Corporate Partnerships

Yale welcomes corporate partnerships and has a history of working with industry leaders to advance research and accelerate new technologies and therapies to market. In 2011, Yale and Gilead Sciences announced a Cancer Research Collaboration—in which Gilead provided $40 million in research support and infrastructure development—to search for the genetic basis and underlying molecular mechanisms of many forms of cancer. The collaboration marks the largest corporate partnership in Yale’s history—and is slated to continue through 2021 with a total of up to $100 million in funding.

A corporate partnership with The Johnson & Johnson Corporate Office of Science and Technology is jointly funding activities at the Yale Molecular Discovery Center on Yale’s West Campus to facilitate early-stage drug development. In May 2012, Yale announced a new partnership with GlaxoSmithKline to design a new class of molecules that will target disease-causing proteins. A $14.5 million collaboration between Yale and AbbVie is backing research into the causes of autoimmune and inflammatory diseases.

The Yale Office of Cooperative Research encourages active engagement in collaborative research with corporate partners to expedite the translation of our research into innovative products, processes and services. To learn more or discuss new opportunities for engagement, contact John Puziss, Director of Licensing.